...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: 6%
6%
2
Dec 14, 2022 02:52PM
3
Dec 14, 2022 03:46PM

Dec 15, 2022 10:11AM
3
Dec 15, 2022 10:27AM

Dec 15, 2022 10:39AM
2
Dec 15, 2022 10:55AM

"KBC, that would be the 6% Royalty steam paid to ZCC generated from the revenue that would come from successful ZEN-3694 in collaboration with BPs drugs. (vis-a-vis trials that are presently ongoing)"

 

yes i believe your correct koo - so if zen sold off zen-3694 would that mean we might see a little piece of that $$ with the majority of cash headed back to rvx? Plus would we still hold a chunk of all thats left or would we be shown the exit door at that point? This is my concern.

1
Dec 15, 2022 11:21AM
1
Dec 15, 2022 11:28AM
1
Dec 15, 2022 11:29AM
1
Dec 15, 2022 11:36AM
Share
New Message
Please login to post a reply